Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm Metastasis × lanreotide × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1 Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 5 Capecitabine 4 pembrolizumab 3 Fluorouracil 3 Cisplatin 3 vinflunine 2 enzalutamide 2 cabazitaxel 2 abiraterone 2 Ipilimumab 2 Haloperidol 2 Androgen Antagonists 2 vedolizumab 1 trifluridine tipiracil drug combination 1 relugolix 1 racemetyrosine 1 nimotuzumab 1 nilutamide 1 lanreotide 1 histrelin 1 futibatinib 1 exemestane 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 bicalutamide 1 beta-Glucans 1 auricularum 1 atezolizumab 1 apatinib 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02288377 2023-01-18

REMINET

Federation Francophone de Cancerologie Digestive

Phase 2/3 Terminated

53 enrolled 11 charts

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡